Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Madeleine Duvic, Rakshandra Talpur, Xiao Ni et al. · Blood · 2006 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Hagop M. Kantarjian, Yasuhiro Oki, Guillermo Garcia‐Manero et al. · Blood · 2006 · 689 citations · Full text

Medicine, Oncology, Pharmacology +16

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

Zhonghua Gao, Paul A. Marks, Xuejun Jiang · Proceedings of the National Academy of Sciences · 2004 · 604 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

Deborah A. Thomas · Blood · 2003 · 569 citations

Medicine, Hematology, Oncology +11

Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

Guillermo Garcia‐Manero, Hagop M. Kantarjian, Blanca Sánchez‐González et al. · Blood · 2006 · 468 citations · Full text

Medicine, Oncology, Pharmacology +10